In recent studies, mounting evidence suggests that compensatory HER3 signaling and subsequent phosphatidylinositol-3-kinase (PI3K)/AKT activation plays a major role in resistance to EGFR-targeted treatments in SCCHN [15, 16]. The gene discussed is AKT1; the disease is head and neck squamous cell carcinoma.